Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Tepotinib (MSC2156119J) is an oral, potent, highly selective MET inhibitor. This open-label, phase I study in healthy volunteers (EudraCT 2013-003226-86) investigated its mass balance (part A) and absolute bioavailability (part B). In part A, six participants received tepotinib orally (498 mg spiked...

Descripción completa

Detalles Bibliográficos
Autores principales: Johne, Andreas, Scheible, Holger, Becker, Andreas, van Lier, Jan Jaap, Wolna, Peter, Meyring, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497692/
https://www.ncbi.nlm.nih.gov/pubmed/32221754
http://dx.doi.org/10.1007/s10637-020-00926-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497692/
https://www.ncbi.nlm.nih.gov/pubmed/32221754
http://dx.doi.org/10.1007/s10637-020-00926-1

Ejemplares similares